PT  - JOURNAL ARTICLE
AU  - Vy, Ha My T.
AU  - Gulamali, Faris F.
AU  - Glicksberg, Benjamin S
AU  - Gutierrez, Orlando
AU  - Cooper, Richard
AU  - Bottinger, Erwin P
AU  - Cho, Judy
AU  - Loos, Ruth J.F.
AU  - Horowitz, Carol R.
AU  - Do, Ron
AU  - Nadkarni, Girish N
TI  - Multi-ethnic polygenic risk modifies the association between <em>APOL1</em> high risk genotypes and chronic kidney disease
AID  - 10.1101/2021.11.12.21266238
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.12.21266238
4099  - http://medrxiv.org/content/early/2021/11/14/2021.11.12.21266238.short
4100  - http://medrxiv.org/content/early/2021/11/14/2021.11.12.21266238.full
AB  - The burden of advanced chronic kidney disease (CKD) falls disproportionately on minorities including African Americans (AAs) and Hispanic Americans (HAs) with admixed ancestry. Even though APOL1 high-risk genotypes increase risk of kidney disease, their penetrance is incomplete, indicating that the modification of APOL1 high risk may be polygenic. For this study, we used three multi-ethnic cohorts with APOL1 high risk genotypes and calculated a multi-ethnic PRS using publicly available summary statistics. We show that CKD risk is significantly modified by a multi-ethnic polygenic risk score. Standardizing population screening for CKD by including APOL1 high-risk genotypes and polygenic risk score may improve risk stratification and outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by R01DK127139.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Icahn School of Medicine at Mount Sinai Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.